2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2135

Musculoskeletal Pain Explains Differences In Function At Time Of Surgery In Black TKR and THR Patients
Abstract Number: 604

Mycophenolate Mofetil Is Not Associated With Reduced Cardiovascular Or Lupus Damage Accumulation In a Cross-Sectional Lupus Cohort Study
Abstract Number: 955

Myeloid Deletion Of SIRT1 Aggravates Serum Transfer Arthritis But Ameliorate Collagen-Induced Arthritis
Abstract Number: 100

Myocardial Infarction and Mortality after Joint Surgery in Patients with Rheumatoid Arthritis Compared with the General Population
Abstract Number: 182

National Quality Forum Measures Among Rheumatoid Arthritis Patients In a Large Managed Care Population
Abstract Number: 399

Nausea and Vomiting During Pregnancy and Spontaneous Abortion In Women With Rheumatoid Arthritis
Abstract Number: 1337

Nearly Pain Free Self-Administration Of Methotrexate Using An Investigational Auto-Injector: Results Of a Phase-2 Clinical Trial In Rheumatoid Arthritis Patients With Mild-To-Severe Functional Limitations
Abstract Number: 1481

Negative Effect Of Glucocorticoids Persistence Therapy On Porosity In Rheumatoid Arthritis Patients Treated With TNFα Blockers
Abstract Number: 1666

Negative Temporal Artery Biopsies: Pathologic Findings Of Patients With Biopsy-Negative Giant Cell Arteritis Compared To Those Of Patients Without Arteritis
Abstract Number: 772

Neovascularization and CD15s Influence Long Distance Migration Of Synovial Fibroblasts From Patients With Rheumatoid Arthritis
Abstract Number: 2730

Netrin1 Is a Critical Autocrine Factor For Osteoclast Differentiation
Abstract Number: 1101

Neuromuscular Taping On Patients With Fibromyalgia May Be a Useful Tool To Relief Muscular Pain
Abstract Number: 2133

Neuropathic Pain After Primary Total Hip and Knee Arthroplasty
Abstract Number: 1861

Neurotrophins Are Involved In Vascular Remodeling Of Giant Cell Arteritis
Abstract Number: 2232

Neutralization of Angiopoietin-2 Enhances the Efficacy of Anti-Tumor Necrosis Factor-Alpha Treatment in a Mouse Model of Rheumatoid Arthritis by Decreasing Cellular Infiltration into the Joint and Protecting Bone

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].